Guangzhou Innogen Pharmaceutical at BIO-Europe 2026

Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website

Guangzhou Innogen Pharmaceutical at BIO-Europe 2026 in Cologne: 1 session (1 talk).

OrganizationBIO-Europe 2026 Attendance
innogenpharm.com
Biotech
Hong Kong-listed developer of metabolic disease drugs whose long-acting GLP-1 drug is approved in China for type 2 diabetes.
Talk
Mon Nov 9
09:00–09:15
Metabolic Diseases: Guangzhou Innogen Pharmaceutical Group Co., Ltd.
A Chinese drugmaker whose long-acting GLP-1 diabetes drug was approved in China in 2025, now being developed for obesity and fatty liver disease.

Explore the full BIO-Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Cologne. Leave your work email and we’ll be in touch.

Privacy

Download the full BIO-Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Guangzhou Innogen Pharmaceutical

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction